發(fā)布時間：2018-10-25 10:52

【摘要】：目的：評價術前予吡柔比星膀胱灌注對非肌層浸潤性膀胱癌患者的復發(fā)和進展的影響。方法：收集135例行經尿道膀胱腫瘤電切術(TUR-BT)治療的非肌層浸潤性膀胱癌患者。根據(jù)納入和排除標準,最后獲得符合標準的120例患者。灌注組40人,術前半小時用吡柔比星30mg+5%葡萄糖50m1行膀胱灌注,而后行TUR-BT;對照組80例,術前未予膀胱灌注。灌注組和對照組均于TUR-BT術后2周開始用吡柔比星30mg+5%葡萄糖50m1行膀胱灌注,1次/周,共8周；而后1次/月,至術后1年,術后均隨訪1年,每3個月行膀胱鏡檢查明確腫瘤有無復發(fā)、進展。結果：隨訪術后1年內,灌注組40例復發(fā)7例,復發(fā)率17.5%,進展2例,進展率5%；對照組80例復發(fā)28例,復發(fā)率35%,進展6例,進展率7.5%。在EORCT評分表分組的中危組中,兩組的復發(fā)率分別為16.8%和36.7%。兩組的總體進展率的差異無統(tǒng)計學意義；兩組總體復發(fā)率和EORCT評分表分組的中危組中的差異具有有統(tǒng)計學意義(P0.05)。結論：術前行吡柔比星膀胱灌注能降低非肌層浸潤性膀胱癌術后1年的復發(fā)率,尤其是按EROCT評分表分組的中危組的患者,是降低非肌層浸潤性膀胱癌術后復發(fā)率的一個有效方法。
[Abstract]:Objective: to evaluate the effect of intravesical instillation of pirarubicin on recurrence and progression of non-myometrial invasive bladder cancer. Methods: a total of 135 patients with non-muscular invasive bladder cancer were treated with transurethral resection of bladder tumor (TUR-BT). According to the inclusion and exclusion criteria, 120 patients who met the criteria were obtained. 40 patients in the perfusion group received intravesical instillation of pirarubicin 30mg 5% glucose 50m1 half an hour before operation, and 80 patients in the TUR-BT; control group were given intravesical perfusion without intravesical instillation before operation. Both the perfusion group and the control group received intravesical instillation of pirarubicin 30mg 5% glucose 50m1 at 2 weeks after TUR-BT for 8 weeks, followed by 1 month to 1 year after operation. Cystoscopy was performed every 3 months to determine the recurrence and progression of the tumor. Results: within one year of follow-up, there were 7 cases of recurrence, 17.5% of recurrence, 2 cases of progression and 5 cases of progression in perfusion group, while in the control group, there were 28 cases of recurrence, 35% of recurrence rate, 6 cases of progression, and 7.5% of progress rate. The recurrence rates of the two groups were 16.8% and 36.7%, respectively. There was no significant difference in the overall progression rate between the two groups; there was significant difference in the overall recurrence rate between the two groups and in the middle risk group in the EORCT scoring table (P0.05). Conclusion: preoperative intravesical instillation of pirarubicin can reduce the recurrence rate of non-myometrial invasive bladder cancer 1 year after operation, especially in the moderate risk group according to the EROCT score. It is an effective method to reduce the recurrence rate of non-myometrial invasive bladder cancer.
【學位授予單位】：廣西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R737.14

【參考文獻】

相關期刊論文 前9條

1 朱清良;馬天波;秦艷麗;;圍手術期灌注吡柔比星預防膀胱癌復發(fā)的療效觀察[J];吉林醫(yī)學;2011年20期

2 田溪泉;邢念增;王勇;李建興;;早期吡柔比星膀胱內灌注預防膀胱癌術后復發(fā)[J];臨床泌尿外科雜志;2006年01期

3 沈善林;劉佃成;于江;馬強;孫丙華;于艷;;三種吡柔比星膀胱灌注保留時間的臨床療效比較研究[J];臨床泌尿外科雜志;2014年11期

4 劉克普;薛慶;張更;袁建林;;術前早期膀胱內灌注吡柔比星預防非肌層浸潤性膀胱癌術后復發(fā)療效分析[J];現(xiàn)代泌尿生殖腫瘤雜志;2010年06期

5 徐慶英,楊華杰,李英蘭;吡柔比星膀胱內灌注治療高齡膀胱癌96例護理體會[J];山東醫(yī)藥;2003年26期

6 王明瓊;羅德康;;經尿道膀胱腫瘤電切術后應用吡柔比星兩種膀胱內灌注方法治療非浸潤性膀胱尿路上皮癌的效果比較[J];腫瘤預防與治療;2014年02期

7 劉尚瑩,蔡邦聯(lián),張泓;膀胱癌與良性前列腺增生同期經尿道電切術(附16例報告)[J];中華泌尿外科雜志;2000年01期

8 凡杰，，謝桐;前列腺增生癥合并膀胱腫瘤（附31例報告）[J];中華泌尿外科雜志;1994年05期

9 顏海標;黃偉華;;膀胱癌灌注化療臨床療效現(xiàn)狀及進展[J];醫(yī)學綜述;2014年04期

本文編號：2293495